Sulfoglycolipids as candidate antiangiogenic radiosensitizers.
Angiogenesis is considered an essential process for the growth of solid tumors and, accordingly, angiogenesis has been a focus of attention for cancer therapy. Although various antiangiogenic agents have been developed, adverse effects and limitations associated with antitumor therapies have recently become apparent. To overcome these problems, combining such agents with chemotherapy or radiotherapy is now strongly recommended in clinical practice. Provided such combination treatment, from the onset of therapy, different strategies in developing antiangiogenic agents should be used to enhance any combinatory effects and reduce adverse effects. By applying the concept of radiosensitizers, a new class of antiangiogenic treatments should now be possible. We recently developed sulfoglycolipids that possess such properties. In this review, we discuss the properties of antiangiogenic radiosensitizers and their potential usefulness.
Miura
Masahiko
M
Oral Radiation Oncology, Tokyo Medical and Dental University, Tokyo, Japan. masa.mdth@tmd.ac.jp
Sakimoto
Ippei
I
Ohta
Keisuke
K
Sugawara
Fumio
F
Sakaguchi
Kengo
K
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D006017:Glycolipids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
D020533:Angiogenesis Inhibitors; D006017:Glycolipids; D011838:Radiation-Sensitizing Agents; D042461:Vascular Endothelial Growth Factor A; C011117:sulfoglycolipids